Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Mar;35(3):548–552. doi: 10.1128/aac.35.3.548

Effects of roxithromycin on fecal bacteria in human volunteers and resistance to colonization in gnotobiotic mice.

S Pecquet 1, E Chachaty 1, C Tancrède 1, A Andremont 1
PMCID: PMC245048  PMID: 2039207

Abstract

The ecological impact of roxithromycin given orally at 300 mg/day on the intestinal floras in six human volunteers was studied. The resulting fecal concentrations of active roxithromycin were in the range of 100 to 200 micrograms/g of feces. Consecutive modifications in the composition of the fecal floras were limited to a decrease in counts of total members of the family Enterobacteriaceae. The rest of the intestinal floras, including the predominant anaerobic floras, changed little. No overgrowth of Pseudomonas aeruginosa, staphylococci, fungi, or highly erythromycin-resistant strains of the family Enterobacteriaceae was observed. The strains of Enterobacteriaceae and of anaerobes isolated during treatment were not markedly more resistant to roxithromycin than those isolated before treatment started. Changes in intestinal resistance to colonization by exogenous microorganisms in gnotobiotic mice inoculated with human fecal flora were studied and were also found to be minimal. The impact of oral roxithromycin on the intestinal microbiota appears to be weaker than that previously observed with oral erythromycin, perhaps because the concentrations of roxithromycin in the feces were lower than those previously found for erythromycin.

Full text

PDF
548

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andremont A., Gerbaud G., Courvalin P. Plasmid-mediated high-level resistance to erythromycin in Escherichia coli. Antimicrob Agents Chemother. 1986 Mar;29(3):515–518. doi: 10.1128/aac.29.3.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andremont A., Gerbaud G., Tancrède C., Courvalin P. Plasmid-mediated susceptibility to intestinal microbial antagonisms in Escherichia coli. Infect Immun. 1985 Sep;49(3):751–755. doi: 10.1128/iai.49.3.751-755.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andremont A., Raibaud P., Tancrède C. Effect of erythromycin on microbial antagonisms: a study in gnotobiotic mice associated with a human fecal flora. J Infect Dis. 1983 Sep;148(3):579–587. doi: 10.1093/infdis/148.3.579. [DOI] [PubMed] [Google Scholar]
  4. Andremont A., Sancho-Garnier H., Tancrede C. Epidemiology of intestinal colonization by members of the family Enterobacteriaceae highly resistant to erythromycin in a hematology-oncology unit. Antimicrob Agents Chemother. 1986 Jun;29(6):1104–1107. doi: 10.1128/aac.29.6.1104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Andremont A., Tancrede C. Reduction of the aerobic Gram negative bacterial flora of the gastro-intestinal tract and prevention of traveller's diarrhea using oral erythromycin. Ann Microbiol (Paris) 1981 Nov-Dec;132 B(3):419–427. [PubMed] [Google Scholar]
  6. Arank A., Syed S. A., Kenney E. B., Freter R. Isolation of anaerobic bacteria from human gingiva and mouse cecum by means of a simplified glove box procedure. Appl Microbiol. 1969 Apr;17(4):568–576. doi: 10.1128/am.17.4.568-576.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Best W. R. On the logarithmid transformation of intestinal bacterial counts. Am J Clin Nutr. 1970 Dec;23(12):1608–1609. doi: 10.1093/ajcn/23.12.1608. [DOI] [PubMed] [Google Scholar]
  8. CHABBERT Y., BOULINGRE H. Modifications pratiques concernant le dosage des antibiotiques en clinique. Rev Fr Etud Clin Biol. 1957 Jun;2(6):636–640. [PubMed] [Google Scholar]
  9. Nilsen O. G. Comparative pharmacokinetics of macrolides. J Antimicrob Chemother. 1987 Nov;20 (Suppl B):81–88. doi: 10.1093/jac/20.suppl_b.81. [DOI] [PubMed] [Google Scholar]
  10. Pecquet S., Andremont A., Tancrède C. Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob Agents Chemother. 1987 Jan;31(1):124–125. doi: 10.1128/aac.31.1.124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pecquet S., Andremont A., Tancrède C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob Agents Chemother. 1986 Jun;29(6):1047–1052. doi: 10.1128/aac.29.6.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sack R. B. Antimicrobial prophylaxis of travelers' diarrhea: a selected summary. Rev Infect Dis. 1986 May-Jun;8 (Suppl 2):S160–S166. doi: 10.1093/clinids/8.supplement_2.s160. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES